RESUMEN
Testosterone (T) and its 17-α epimer, epitestosterone (EpiT), are described as having non-classical effects in addition to their classical androgen actions via the intracellular androgen receptor (iAR). The actions of these androgens play an essential role in triggering factors that shift Sertoli cells from the proliferation phase to the maturation phase. This process is essential for successful spermatogenesis and normal fertility. The aim of this work was to investigate the difference between T and EpiT effects in normal and in chemically castrated Wistar rats. We also tested the effects of these hormones when the iAR-dependent pathways were inhibited by the antiandrogen flutamide. Rats were chemically castrated on postnatal day (pnd) 5 using EDS, a cytotoxic agent that promotes apoptosis of Leydig cells, reducing androgen levels. Then, animals received replacement with T or EpiT and were treated or not with flutamide from pnd 6 to pnd 13 or 20 and were euthanized on pnd 14 and 21. Animals treated with EpiT and flutamide had lower body weight overall. Epididymis weight was also reduced in animals treated with EpiT and flutamide. Flutamide per se reduced epididymis weight at both ages (pnd 14 and 21). Testicular weight and the testicular/body weight ratio were reduced in EDS animals, and flutamide further reduced this weight in animals which received T replacement. EDS administration reduced mRNA levels of both AMH (anti-Müllerian hormone) and its receptor, AMHR2, at pnd 14. In the testes of flutamide-treated animals, EpiT reduced AMH, and both T and EpiT replacement diminished AMHR2 mRNA expression also on pnd 14. EDS decreased iAR expression, and androgen replacement did not change this effect on pnd 21. In rats receiving flutamide, only those also receiving T and EpiT replacement exhibited decreased iAR expression. An increase in connexin 43 expression was observed in animals treated with EpiT without flutamide, whereas in rats treated with flutamide, both hormones were ineffective to increase connexin 43 expression reduced by EDS. Our results suggest that EpiT has an antiandrogen effect on androgen-sensitive tissues such as the epididymis. Nonetheless, the effects of T and EpiT on testicular development parameters are similar. Both hormones may act through their iAR-independent non-classical pathway, regulating AMH and AMHR2, as well as iAR expression.
Asunto(s)
Hormona Antimülleriana/metabolismo , Epitestosterona/farmacología , Testículo/crecimiento & desarrollo , Testículo/metabolismo , Testosterona/farmacología , Andrógenos/farmacología , Animales , Hormona Antimülleriana/genética , Barrera Hematotesticular/efectos de los fármacos , Barrera Hematotesticular/metabolismo , Peso Corporal/efectos de los fármacos , Conexina 43/metabolismo , Masculino , Tamaño de los Órganos/efectos de los fármacos , Especificidad de Órganos/efectos de los fármacos , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas Wistar , Receptores Androgénicos/genética , Receptores Androgénicos/metabolismo , Receptores de Factores de Crecimiento Transformadores beta/genética , Receptores de Factores de Crecimiento Transformadores beta/metabolismo , Testículo/efectos de los fármacosRESUMEN
Epitestosterone is the 17α-epimer of testosterone and has been described as an anti-androgen, since it inhibits the effects produced by testosterone and dihydrotestosterone via the nuclear androgen receptor (nAR). However, epitestosterone also displays an effect which is similar to the non-classical effect of testosterone, depolarizing the membrane potential of Sertoli cells and inducing a rapid Ca2+ uptake. This study aimed to investigate the effects of a treatment with epitestosterone on developmental parameters of immature rats. Animals were chemically castrated by using the gonadotropin-releasing hormone (GnRH) antagonist cetrorelix and then received a replacement of 7 days with epitestosterone or testosterone. Replacement with either epitestosterone or testosterone restored the anogenital distance (AGD) and testicular weight which had been reduced by chemical castration. The immunocontent of nAR and the nAR-immunoreactivity were reduced by epitestosterone treatment in the testis of both castrated and non-castrated animals. Furthermore, testosterone was unable of changing the membrane potential of Sertoli cells through its non-classical action in the group of animals castrated and replaced with epitestosterone. In conclusion, in relation to the level of protein expression of nAR epitestosterone acts as an anti-androgen. However, it acts in the same way as testosterone when genital development parameters are evaluated. Moreover, in castrated rats epitestosterone suppressed the non-classical response of testosterone, changing the pattern of testosterone signalling via a membrane mechanism in Sertoli cells.
Asunto(s)
Castración , Epitestosterona/farmacología , Terapia de Reemplazo de Hormonas , Testículo/crecimiento & desarrollo , Testosterona/farmacología , Animales , Regulación del Desarrollo de la Expresión Génica/efectos de los fármacos , Hormona Liberadora de Gonadotropina/análogos & derivados , Hormona Liberadora de Gonadotropina/antagonistas & inhibidores , Hormona Liberadora de Gonadotropina/metabolismo , Hormona Liberadora de Gonadotropina/farmacología , Masculino , Potenciales de la Membrana/efectos de los fármacos , Ratas Wistar , Receptores Androgénicos/genética , Receptores Androgénicos/metabolismo , Túbulos Seminíferos/efectos de los fármacos , Túbulos Seminíferos/metabolismo , Células de Sertoli/efectos de los fármacos , Células de Sertoli/metabolismo , Testículo/efectos de los fármacosRESUMEN
The intratesticular testosterone concentration is high during the early postnatal period although the intracellular androgen receptor expression (iAR) is still absent in Sertoli cells (SCs). This study aimed to evaluate the non-classical effects of testosterone and epitestosterone on calcium uptake and the electrophysiological effects of testosterone (1µM) on SCs from rats on postnatal day (pnd) 3 and 4 with lack of expression of the iAR. In addition, crosstalk on the electrophysiological effects of testosterone and epitestosterone with follicle stimulating hormone (FSH) in SCs from 15-day-old rats was evaluated. The isotope (45)Ca(2+) was utilized to evaluate the effects of testosterone and epitestosterone in calcium uptake. The membrane potential of SCs was recorded using a standard single microelectrode technique. No immunoreaction concerning the iAR was observed in SCs on pnd 3 and 4. At this age, both testosterone and epitestosterone increased the (45)Ca(2+) uptake. Testosterone promoted membrane potential depolarization of SCs on pnd 4. FSH application followed by testosterone and epitestosterone reduced the depolarization of the two hormones. Application of epitestosterone 5 min after FSH resulted in a delay of epitestosterone-promoted depolarization. The cell resistance was also reduced. Thus, in SCs from neonatal Wistar rats, both testosterone and epitestosterone act through a non-classical mechanism stimulating calcium uptake in whole testes, and testosterone produces a depolarizing effect on SC membranes. Testosterone and epitestosterone stimulates non-classical actions via a membrane mechanism, which is independent of iAR. FSH and testosterone/epitestosterone affect each other's electrophysiological responses suggesting crosstalk between the intracellular signaling pathways.
Asunto(s)
Andrógenos/farmacología , Epitestosterona/farmacología , Células de Sertoli/fisiología , Animales , Animales Recién Nacidos , Calcio/metabolismo , Hormona Folículo Estimulante/farmacología , Hormona Folículo Estimulante/fisiología , Masculino , Potenciales de la Membrana , Ratas Wistar , Células de Sertoli/efectos de los fármacos , Testículo/citología , Testículo/efectos de los fármacosRESUMEN
Epitestosterone is the 17α-epimer of testosterone. This steroid possesses antiandrogenic activities. The mechanism of action of epitestosterone has not been elucidated. The aim of this study was to investigate the nonclassical effect of epitestosterone on the membrane of Sertoli cells in proliferative phase (rats aged 15 days) and in nonproliferative phase (rats aged 21 and 35 days). The membrane potential of Sertoli cells was recorded using a standard single microelectrode technique. Epitestosterone (0.5, 1, and 2 µM) or testosterone (1 µM) was administered alone and after infusion with flutamide (1 µM), verapamil (100 µM), or U-73122 (2 µM). The testes of rats aged 12-15 days were preincubated with 45Ca2+ with or without flutamide (1 µM) and incubated with epitestosterone (1 µM) or testosterone (1 µM). Epitestosterone and testosterone produced a depolarization in the membrane potential and increased the membrane input resistance on Sertoli cells from rats of all 3 ages. The effect of epitestosterone did not change after perfusion with flutamide. Epitestosterone increased 45Ca2+ uptake within 5 min and this effect was not inhibited by flutamide. The absence of an effect by flutamide suggests that epitestosterone acts independently of the intracellular androgen receptor. The depolarizing effect was inhibited by verapamil, a voltage-dependent calcium channel blocker, and by U-73122, a phospholipase C inhibitor. These results indicate that epitestosterone acts on the membrane via a nonclassical signaling pathway; the effect was similar to the testosterone action on membrane of Sertoli cells in whole seminiferous tubules from rat testes.
Asunto(s)
Membrana Celular/fisiología , Epitestosterona/farmacología , Túbulos Seminíferos/citología , Células de Sertoli/citología , Células de Sertoli/fisiología , Testosterona/farmacología , Animales , Calcio/metabolismo , Canales de Calcio/metabolismo , Canales de Calcio Tipo L/metabolismo , Membrana Celular/efectos de los fármacos , Flutamida/farmacología , Espacio Intracelular/efectos de los fármacos , Espacio Intracelular/metabolismo , Masculino , Potenciales de la Membrana/efectos de los fármacos , Ratas , Ratas Wistar , Receptores Androgénicos/metabolismo , Células de Sertoli/efectos de los fármacos , Fosfolipasas de Tipo C/metabolismoRESUMEN
Testosterone and other anabolic-androgenic steroids enhance athletic performance in men and women. As a result, exogenous androgen is banned from most competitive sports. However, due to variability in endogenous secretion, and similarities with exogenous testosterone, it has been challenging to establish allowable limits for testosterone in competition. Endogenous androgen production is dynamically regulated by both exercise and winning in competition. Furthermore, testosterone may promote athletic performance, not only through its long-term anabolic actions, but also through rapid effects on behavior. In women, excess production of endogenous testosterone due to inborn disorders of sexual development (DSD) may convey a competitive advantage. For many years, female competitors have been subject to tests of sexual genotype and phenotype known as gender verification. Although gender verification has not identified any normal man competing as a woman, this process has identified women athletes with DSD. As understanding of DSD has expanded in recent years, women with DSD are increasingly able to continue athletic competition.
Asunto(s)
Rendimiento Atlético , Testosterona/fisiología , Anabolizantes/farmacología , Doping en los Deportes/métodos , Epitestosterona/biosíntesis , Epitestosterona/sangre , Epitestosterona/farmacología , Femenino , Humanos , Masculino , Aberraciones Cromosómicas Sexuales , Análisis para Determinación del Sexo/métodos , Diferenciación Sexual , Testosterona/biosíntesis , Testosterona/metabolismo , Testosterona/farmacocinética , Testosterona/farmacologíaRESUMEN
Amateau and McCarthy's findings published in Nature Neuroscience (June 2004) are noteworthy for suggesting a role for prostaglandins in sexual development. However, evidence suggests that in manipulating PGE2, they unknowingly implicated 3alpha-hydroxysteroid dehydrogenase [E.C. 1.1.1.50], 3(or 17)alpha-hydroxysteroid dehydrogenase [E.C. 1.1.1.209] and their respective products, androsterone (ADT) and epitestosterone (EpiT), in the developmental masculinization of sex behavior. EpiT is generally regarded as a hormonally inactive 17alpha-epimer of testosterone (T). In rats, the kidney is the primary site of EpiT formation, whereas in humans it originates from the gonads, with only a small contribution secreted by the adrenals. Because the ratio of T to EpiT is nearly constant, it is presently used for assessing steroid abuse in competitive sports, where the World Anti-Doping Agency (WADA) considers a T/EpiT ratio >4 evidence of T doping. Despite its central role in the detection of illict anabolic steroid use, our knowledge of factors effecting EpiT production is poor. Clues in the literature, however, reveal that prostaglandin-mediated processes, such as LHRH release, may influence its production. Antimycotics, NSAIDs, and opioid analgesics used in sports medicine are all known to effect prostaglandin E2 synthesis. Primary PGs are potent inhibitors of ADT oxidation, while indomethacin, a prostaglandin blocker, powerfully inhibits 3alpha-HSD reduction and ADT oxidation. This is significant because ADT inhibits the oxidation of EpiT, and may modulate its antiandrogenic and neuroprotective effects. It is hypothesized that the T/EpiT ratio is increased by COX-2 inhibitors and opiod analgesics, and decreased by antimycotics that do not impair testosterone biosynthesis. Given the devastating personal and career consequences that may result from false positive drug tests, substantive research on the effects of PGE2 manipulations on EpiT is warranted.
Asunto(s)
Doping en los Deportes , Epitestosterona/farmacología , Conducta Sexual , Desarrollo Sexual/fisiología , Deportes , Androsterona/metabolismo , Animales , Inhibidores de la Ciclooxigenasa/farmacología , Dinoprostona/metabolismo , Dinoprostona/farmacología , Epitestosterona/metabolismo , Femenino , Humanos , Indometacina/farmacología , Masculino , Modelos Animales , Conducta Sexual Animal/efectos de los fármacos , Desarrollo Sexual/efectos de los fármacos , Testosterona/metabolismoRESUMEN
A series of 4- and/or 17alpha-substituted testosterone analogues has been incubated with the hydroxylating fungus Fusarium culmorum AM282. It was found that 19-norandrostenedione, 19-nortestosterone, 4-methoxytestosterone, 4-methyltestosterone, and 4-chloro-17alpha-methyltestosterone were hydroxylated exclusively or mainly at the 6beta-position. The mixtures of 6beta-, 15alpha-, and 12beta- or 11alpha-monohydroxy derivatives were obtained from 17alpha-methyltestosterone and 17alpha-ethyl-19-nortestosterone--the substrates with alkyl group at C-17alpha. 4-Chlorotestosterone was predominantly hydroxylated at 15alpha-position, but the reaction was accompanied by the reduction of 4-en-3-one system, which proceeded in the sequence: reduction of ketone to 3beta-alcohol and then reduction of the double 4,5 bond. The results obtained indicate an influence of stereoelectronic and steric effects of substitutes on regioselectivity of the hydroxylation of 4-en-3-one steroids by F. culmorum.
Asunto(s)
Epitestosterona/metabolismo , Fusarium/fisiología , Biotransformación/efectos de los fármacos , Biotransformación/fisiología , Epitestosterona/análogos & derivados , Epitestosterona/farmacología , Hidroxilación/efectos de los fármacosRESUMEN
Epitestosterone has been identified as a natural component of biological fluids of several mammals including man. For a long time it was believed that it is a metabolite without any hormonal activity and without any marked relationship to the hormonal state in health and disease. Neither the biosynthetic pathway nor the site of its formation in man have been unequivocally confirmed to date. It apparently parallels the formation of testosterone (T), but on the other hand its concentration is not influenced by exogenous administration of testosterone. This fact creates the basis of the present doping control of testosterone abuse. In 1989 an observation was presented in a dermatological study that epitestosterone exerts an effect counteracting the action of testosterone on flank organ of Syrian hamster. Further studies showed that a complex action consisting of competitive binding of epitestosterone to androgen receptor, of inhibition of testosterone biosynthesis and its reduction to dihydrotestosterone and of antigonadotropic activity could be demonstrated in rat, mice and human tissues. It can be presumed that epitestosterone as a natural hormone can contribute to the regulation of such androgen dependent events as, e.g. the control of prostate growth or body hair distribution.
Asunto(s)
Epitestosterona/fisiología , Antagonistas de Andrógenos/farmacología , Animales , Doping en los Deportes/métodos , Epitestosterona/farmacología , Humanos , Receptores Androgénicos/efectos de los fármacos , Receptores Androgénicos/metabolismo , Testosterona/metabolismoRESUMEN
Steroidal antiandrogen epitestosterone was administered to intact male mice and its effect on seminal vesicles, kidney, femoral bones and circulating calcium, phosphate, testosterone and LH were compared with controls and castrated animals. Epitestosterone was previously reported as an inhibitor the binding of androgens to their receptors, an inhibitor of the formation of dihydrotestosterone from testosterone and a modulator of estradiol-estrone conversion. In the present study it is demonstrated that it decreased the weight of kidney, seminal vesicles and bone density, ash weight and calcium and phosphate content of femoral bone tissue significantly, although not to the values as low as those seen in castrated animals. Thus in mice epitestosterone effects could be classified as antiandrogenic.
Asunto(s)
Antagonistas de Andrógenos/farmacología , Epitestosterona/farmacología , Animales , Densidad Ósea/efectos de los fármacos , Fémur/anatomía & histología , Fémur/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos , Orquiectomía , Tamaño de los Órganos/efectos de los fármacos , Vesículas Seminales/anatomía & histología , Vesículas Seminales/efectos de los fármacos , Testosterona/antagonistas & inhibidoresRESUMEN
OBJECTIVE: The concentrations of epitestosterone in human serum correlates negatively with that of estradiol. The possible explanation of this relation was addressed, and the influence of epitestosterone on kinetics of estradiol formation in vitro was evaluated. METHODS: The concentration of epitestosterone was measured in serum of 54 men participating in a screening program for prostate disease. Epitestosterone inhibition of aromatase and 17beta-hydroxysteroid dehydrogenase activities was tested in vitro in the system consisting of human placental microsomes, NADPH or NAD and NADP respectively, and epitestosterone in increasing concentrations. Testosterone, androstenedione, estrone and 17beta-estradiol were utilized as substrates. RESULTS: A significant negative correlation between epitestosterone and estradiol levels in human male serum was found. No inhibition of aromatase activity was observed; however, inhibition of 17beta-hydroxysteroid dehydrogenase was found preferentially in the direction leading to oxidation of the C-17 hydroxy group. The inhibitory effect of epitestosterone was more pronounced with androgens as substrates. CONCLUSION: Epitestosterone could influence the formation of estradiol in vitro rather by inhibition of 17beta-hydroxysteroid dehydrogenase than by blocking aromatase activity.
Asunto(s)
Inhibidores de la Aromatasa , Epitestosterona/farmacología , Estradiol/biosíntesis , Placenta/enzimología , 17-Hidroxiesteroide Deshidrogenasas/metabolismo , Anciano , Aromatasa/metabolismo , Femenino , Humanos , Técnicas In Vitro , Masculino , Persona de Mediana Edad , Distribución Normal , Placenta/efectos de los fármacos , Testosterona/metabolismoRESUMEN
With regard to previous finding of an inhibitory activity of furosemide on 11 beta-hydroxysteroid dehydrogenase, 16 other commonly used diuretics have been tested as to their ability to inhibit rat renal, and in four instances also testicular 11 beta-hydroxysteroid dehydrogenase, using glycerrhetinic acid as a standard. In addition, epitestosterone has been tested as well, with respect to its recently demonstrated inhibitory activity on several other enzymes of androgen biosynthesis. Besides corticosterone, 11 beta-hydroxy-4-androstene-3,17-dione has been used as a substrate. Of all drugs studied, quinapril, dihydralazin, trandolapril, metipamid, methyldopa, betaxolol only appeared to be weak inhibitors of 11 beta-hydroxysteroid dehydrogenase, with an inhibitory activity 10-28% of that of glycyrrhetinic acid. Using corticosterone as a substrate, epitestosterone displayed a weak inhibitory activity with Ki 850, 1200 nmol/l and Vmax 2420, 3900 nmol/l.min for renal and testicular enzyme, respectively. In contrast to kidneys, the testicular 11 beta-hydroxysteroid dehydrogenase accepted also 11 beta-hydroxy-4-androstene-3,17-dione as a substrate, which could be inhibited by epitestosterone (Ki 1490 nmol/l, Vmax 1150 nmol/l.min). The results represent further evidence for different substrate specificity of renal and testicular 11 beta-hydroxysteroid dehydrogenase.
Asunto(s)
Antihipertensivos/farmacología , Diuréticos/farmacología , Inhibidores Enzimáticos/farmacología , Hidroxiesteroide Deshidrogenasas/antagonistas & inhibidores , Riñón/enzimología , Testículo/enzimología , 11-beta-Hidroxiesteroide Deshidrogenasas , Antagonistas Adrenérgicos beta/farmacología , Androstenodiona/análogos & derivados , Androstenodiona/metabolismo , Animales , Corticosterona/metabolismo , Epitestosterona/farmacología , Ácido Glicirretínico/farmacología , Riñón/ultraestructura , Masculino , Microsomas/enzimología , Ratas , Especificidad por SustratoRESUMEN
Nonsteroidal antiandrogen casodex and steroidal antiandrogen epitestosterone were administered to intact male mice, and their effect on femoral bones and circulating calcium, phosphate, testosterone, and LH were compared with controls and castrated animals. Pure antiandrogen casodex in a dose used in humans for treatment of prostate cancer decreased the weight of seminal vesicles, organ which is highly sensitive to the androgenic effect, increased insignificantly the concentration of LH and of testosterone, but did not have any effect on bone density or mineral content of bone. Epitestosterone, which not only inhibits the binding of androgens to their receptors but also inhibits the formation of dihydrotestosterone from testosterone, and is reported to interfere with aromatization of testosterone to estrogens, decreased the bone density, ash weight, and calcium and phosphate content of femoral bone tissue significantly, although not to values as low as those seen in castrated animals.
Asunto(s)
Antagonistas de Andrógenos/farmacología , Anilidas/farmacología , Huesos/efectos de los fármacos , Huesos/metabolismo , Epitestosterona/farmacología , Antagonistas de Andrógenos/toxicidad , Anilidas/toxicidad , Animales , Densidad Ósea/efectos de los fármacos , Enfermedades Óseas Metabólicas/etiología , Calcio/sangre , Calcio/metabolismo , Epitestosterona/toxicidad , Humanos , Hormona Luteinizante/sangre , Masculino , Ratones , Nitrilos , Orquiectomía , Tamaño de los Órganos/efectos de los fármacos , Fosfatos/sangre , Fosfatos/metabolismo , Factores de Riesgo , Vesículas Seminales/efectos de los fármacos , Vesículas Seminales/patología , Testículo/fisiología , Testosterona/sangre , Compuestos de TosiloRESUMEN
Sexual differences on thyroxin 5'-deiodinase (5'-D) in the Harderian gland of Syrian hamsters were investigated. We compared the 24-h profile of 5'-D activity in male and female hamsters, observing a clear rhythm in males but not in females. Female values were always significantly higher than male ones. After pinealectomy day/night variations in male 5'-D activity at the time points studied were abolished, results that are in correlation with serum thyroid hormones. We also studied the regulation by androgen of the enzyme activity. Basal 5'-D activity increased in castrated males and levels fell when animals were implanted with testosterone or its product 5 alpha-dihydrotestosterone (DHT). Female 5'-D activity was also inhibited by androgens. As only the addition of DHT in the presence of epitestosterone, an inhibitor of the conversion of testosterone on DHT, in castrated males was able to decrease 5'-D activity to the control animal levels, we suggest a probable direct effect of DHT by itself.
Asunto(s)
Andrógenos/metabolismo , Glándula de Harder/enzimología , Yoduro Peroxidasa/metabolismo , Glándula Pineal/cirugía , Caracteres Sexuales , Andrógenos/sangre , Andrógenos/farmacología , Animales , Cricetinae , Dihidrotestosterona/metabolismo , Dihidrotestosterona/farmacología , Epitestosterona/metabolismo , Epitestosterona/farmacología , Femenino , Glándula de Harder/efectos de los fármacos , Yoduro Peroxidasa/efectos de los fármacos , Masculino , Mesocricetus , Orquiectomía , Glándula Pineal/fisiología , Testosterona/sangre , Testosterona/metabolismo , Testosterona/farmacología , Factores de TiempoRESUMEN
The effects of 3-week treatment with increasing doses of epitestosterone (ET) on gonadotrophin gene expression and secretion, on testosterone and 5 alpha-dihydrotestosterone (DHT) levels, and on the weight of testes and prostates, were studied in intact adult male rats. The hormones were delivered by means of silastic capsules of different lengths filled with the steroid. One group of rats received testosterone (T) instead of ET, to compare the results with previous studies concerning the testosterone effect. The controls were given capsules with glucose only. Treatment with ET, as well as with T, significantly reduced the weights of prostates. When the data from ET-treated rats and controls were combined, a significant negative correlation (P < 0.001) was found between the weight of prostates and serum ET. T, in contrast to ET, also decreased significantly the weights of testes, ET treatment caused a significant reduction of serum T levels but only an insignificant decline of DHT levels, independent of the dose. Serum and pituitary (p) luteinizing hormone (LH) levels in the ET-treated rats did not change. Pituitary mRNA contents for the beta LH subunit (beta LH-mRNA) showed a dose-dependent significant increase, up to 170% (P < 0.01), with ET treatment. pFSH decreased with the lowest ET (2 cm) dose (P < 0.05), but no change was observed with the other doses. The mRNA for the common alpha-subunit also increased with the ET load. In conclusion, ET acts at several sites in the regulation of gonadotrophin formation and release. It enhances the steady-state mRNA levels of both gonadotrophins in the pituitary.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Epitestosterona/farmacología , Gonadotropinas Hipofisarias/metabolismo , Próstata/efectos de los fármacos , Animales , Dihidrotestosterona/sangre , Relación Dosis-Respuesta a Droga , Hormona Folículo Estimulante/metabolismo , Hormonas Glicoproteicas de Subunidad alfa/genética , Hibridación in Situ , Hormona Luteinizante/genética , Hormona Luteinizante/metabolismo , Masculino , Tamaño de los Órganos/efectos de los fármacos , Hipófisis/efectos de los fármacos , Hipófisis/metabolismo , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Testículo/efectos de los fármacos , Testosterona/sangreRESUMEN
Epitestosterone has been shown previously to counteract the testosterone activity in some experimental models. In the present study the activity of epitestosterone in an in vitro model of human LNCaP/FCS prostate cells and in vitro in Dunning R 3327-GH rat prostate carcinoma was tested. In LNCaP/FGC cells cultivated with fetal calf serum (FCS) treated with dextran-coated charcoal epitestosterone displayed rather androgenic than antiandrogenic properties, whereas the cultivation with native FCS resulted in a very weak inhibition of tumour cell growth with epitestosterone in higher concentration. The growth of Dunning R 3327-GH carcinoma of prostate was very weakly enhanced by epitestosterone alone as late as at the end of the 5-week experiment. Epitestosterone did not significantly inhibit the testosterone stimulated tumour growth.
Asunto(s)
Epitestosterona/farmacología , Neoplasias Hormono-Dependientes/tratamiento farmacológico , Neoplasias de la Próstata/tratamiento farmacológico , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/cirugía , Animales , División Celular/efectos de los fármacos , Modelos Animales de Enfermedad , Humanos , Masculino , Neoplasias Hormono-Dependientes/cirugía , Orquiectomía , Neoplasias de la Próstata/cirugía , Ratas , Ratas Endogámicas F344 , Testosterona/farmacología , Células Tumorales Cultivadas/efectos de los fármacosRESUMEN
Epitestosterone (17 alpha-hydroxy-4-androsten-3-one) inhibited competitively 17 alpha-hydroxylation of pregnenolone and subsequent C17,20-side chain cleavage of resulting 17 alpha-hydroxypregnenolone using microsomal preparations from the human testis. The inhibition constants for 17 alpha-hydroxylase and C17,20-lyase with 5-ene-precursors of C21-steroids were 96 and 12.4 mumol/l, respectively.
Asunto(s)
Aldehído-Liasas/antagonistas & inhibidores , Inhibidores Enzimáticos del Citocromo P-450 , Epitestosterona/farmacología , Esteroide 17-alfa-Hidroxilasa/antagonistas & inhibidores , Testículo/enzimología , Humanos , Cinética , MasculinoRESUMEN
Immature ovariectomized female rats primed with estradiol or without estrogen priming were treated with epitestosterone i.p. After 7 h blood was collected and LH and FSH levels were determined. The dose-response relationship was a biphasic one. LH and less markedly FSH levels decreased under epitestosterone treatment with doses up to 10 mg, whereas at higher doses an increase of gonadotrophins was observed.
Asunto(s)
Epitestosterona/farmacología , Hormona Folículo Estimulante/sangre , Hormona Luteinizante/sangre , Animales , Relación Dosis-Respuesta a Droga , Epitestosterona/administración & dosificación , Estradiol/farmacología , Femenino , Inyecciones Intraperitoneales , Ovariectomía , Ratas , Ratas Wistar , Receptores de Estrógenos/efectos de los fármacosRESUMEN
Epitestosterone (17 alpha-hydroxy-4-androsten-3-one) inhibits both 17 alpha-hydroxylation and consequent side chain cleavage of the resulting 17 alpha-hydroxyprogesterone in the rat testicular microsomes. The inhibitory activity in terms of the Ki is 2 and 1.5 times as high, respectively, as that of cyproterone acetate.
Asunto(s)
Epitestosterona/farmacología , Testículo/efectos de los fármacos , Animales , Ciproterona/metabolismo , Técnicas In Vitro , Masculino , Microsomas/metabolismo , Oxigenasas de Función Mixta/metabolismo , Ratas , Testosterona/biosíntesisRESUMEN
Epitestosterone (17 alpha-hydroxy-4-androsten-3-one), a normal constituent of human plasma and urine, prevents the testosterone induced changes in body weight and in organ weights of seminal vesicles and kidney of castrated male mice. It competes with methyltrienolone in the binding to rat prostate cytosol (Ki = 29.8 nmol.l-1. It inhibits also the activity of 5 alpha-reductase from rat prostate pellet (Ki = 1.2 mumols.l-1). Epitestosterone can be considered as a weak antiandrogen in the term of displacement of androgen from receptor binding and as an efficient inhibitor of 5 alpha-reductase.
Asunto(s)
Epitestosterona/farmacología , Receptores Androgénicos/metabolismo , Testosterona/antagonistas & inhibidores , Testosterona/farmacología , Animales , Colestenona 5 alfa-Reductasa , Ciproterona/análogos & derivados , Ciproterona/farmacología , Acetato de Ciproterona , Citosol/metabolismo , Masculino , Ratones , Tamaño de los Órganos/efectos de los fármacos , Oxidorreductasas/antagonistas & inhibidores , Próstata/enzimología , RatasRESUMEN
The action of the endogenous steroid epitestosterone administered to castrated male mice substituted with testosterone propionate is manifested by reduced weight increments and a reduced relative weight of their seminal vesicles and kidneys. Epitestosterone in vitro displaces androgens from their bond with receptors in cytosol from rat prostates and markedly inhibits the testosterone transformation to the more effective androgen dihydrotestosterone. Epitestosterone can be thus defined as a true endogenous antiandrogen; to its action at the receptor level a potent inhibitory effect on 5 alpha-reductase must be added.